Northerner
Admin (Retired)
- Relationship to Diabetes
- Type 1
French pharmaceutical company Servier is making a big bet that a tiny drug-loaded implantable pump being developed by a Boston-based startup will transform the global market for patients with diabetes.
Servier has agreed to pay Intarcia Therapeutics Inc. $171 million up front, with potential additional payments that could increase the total to more than $1 billion, for rights to co-develop the device for most markets outside the U.S., the companies said. Closely held Intarcia retains full rights to the treatment for the U.S. and Japan.
The agreement amounts to a significant validation of the potential for the experimental pump, a matchstick-sized device that delivers a continuous dose of the drug exenatide to patients for up to a year. The pump is intended to address a major issue in treatment of Type 2 diabetes: the failure of most patients to stay on pills or take injections required to control their blood sugar.
http://online.wsj.com/articles/french-drug-firm-bets-on-tiny-diabetes-device-1415768461
Looks interesting 🙂
Servier has agreed to pay Intarcia Therapeutics Inc. $171 million up front, with potential additional payments that could increase the total to more than $1 billion, for rights to co-develop the device for most markets outside the U.S., the companies said. Closely held Intarcia retains full rights to the treatment for the U.S. and Japan.
The agreement amounts to a significant validation of the potential for the experimental pump, a matchstick-sized device that delivers a continuous dose of the drug exenatide to patients for up to a year. The pump is intended to address a major issue in treatment of Type 2 diabetes: the failure of most patients to stay on pills or take injections required to control their blood sugar.
http://online.wsj.com/articles/french-drug-firm-bets-on-tiny-diabetes-device-1415768461
Looks interesting 🙂